Peter Keks

#HEX #PLS #PlsX 💵🥷🏻

[AtaiBeckley Inc @ataibeckley]

Delighted to share our latest article, The Challenge of Commercialising Psychedelic Medicines, in the Summer 2026 edition of @EBRmagazine.

Written by our Chief Medical Officer, Dr Kevin Craig, the article explores the path to clinical adoption for psychedelics in mental health - covering scalability, real-world delivery, and next-gen approaches bridging innovation with practical care.

Read the piece here (pages 53 - 55): https://t.co/wMbEaBCsRC

[Theo Von @TheoVon]

Praying for these brave women

[Christian Angermayer @C_Angermayer]

Today, Enhanced Group - the parent company of the @enhanced_games and the “Live Enhanced” telehealth platform - begins trading on the New York Stock Exchange under the ticker $ENHA after its successful merger with "A Paradise SPAC".

I believe Enhanced Group has the potential to become a generation-defining company - one that reshapes how we think about sport, health, and human performance, with impact far beyond its core business.

Enhanced Group combines a global sports franchise with a next-generation consumer health platform in a way the market has never seen before.

Additionally, Enhanced Group is right now conducting the largest clinical study ever undertaken to explore the effects of medical performance-enhancing drugs in unprecedented detail. I can already tell you: the findings will be fascinating and are likely to shatter many long-held myths and “urban legends”. And will potentially allow the company to create valuable intellectual property.

Read my blog post to learn more about the vision and opportunity behind the company.

And follow @enhanced_games and me for updates - the next two weeks should be full of exciting developments as we put the final touches on the Games.

Most importantly: tune in on May 24 at 5pm PST. On all major platforms.

After that night, the world of sports may never look the same again.

[Christian Angermayer @C_Angermayer]

Today’s Presidential Executive Order on #psychedelics marks a major milestone in the history of these valuable substances.

It corrects a fundamental mistake made in 1970, when President Nixon established the Controlled Substances Act (CSA) and classified psychedelics as Schedule I substances - a designation that had no basis. For largely political reasons, these highly promising compounds were pushed out of the medical realm and into illegality.

Now, they are coming back - with force.

The executive order is directing the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA), the Department of Justice and other federal agencies to reduce the red tape and restrictions that have long stymied researchers and biotech companies in the field.

As a result, I expect drug approval processes to accelerate and become less costly.

I am very proud that @ataibeckley is at the forefront of this field, with one of the broadest pipelines in psychedelics, including clinical programs focused on DMT, 5-MeO-DMT, R-MDMA and – as previously disclosed - ibogaine and additional novel, discovery compounds in various stages of preclinical development.

Since I founded AtaiBeckley in 2017, and seed-funded @COMPASSPathway that same year, these two companies have raised more than $1.5 billion to advance clinical research and development of psychedelic therapies.

As access to capital was limited early on - since most investors dismissed the idea as crazy - I invested over $100 million of my own capital and have never sold a single $ATAI share (nor do I intend to).

The public sentiment around psychedelics as FDA-regulated drugs has gone from “this is a crazy idea that will ruin your career” to being on the verge of what the market anticipates will be the first regulatory approval of a psychedelic with COMP360… all in less than a decade. What a journey.

But we are still only at the beginning.

I strongly believe the world will benefit from the full spectrum of psychedelic compounds that demonstrate medical and commercial value. I also believe that delivery mechanisms and treatment duration are critical, as these therapies must fit within the commercial realities and infrastructure of the U.S. and global healthcare systems.

That conviction is exactly why AtaiBeckley has built such a broad and diversified pipeline with a focus on short-acting psychedelics:
https://t.co/YkpR93738B

Once approved, I expect physicians will determine which treatments are best suited to specific patient profiles. Over time, better data and real-world evidence will significantly improve this matching - delivering the right FDA-approved treatment to the right patient.

This level of presidential attention also reinforces another long-held belief of mine: the support – and potential use - for psychedelic therapies is far larger and broader than most people have historically assumed.

Take once more AtaiBeckley as an example. Most analysts currently model compounds like BPL-003 and VLS-01 primarily within treatment-resistant depression (TRD) - patients who have already failed at least two antidepressant treatments. But my own personal view (and ultimate vision) would be to progress to these treatments sooner, especially when existing treatments often have limited efficacy and significant side effects.

Given the favorable safety profiles and promising efficacy of psychedelics we are seeing in the clinical trials run to date, and based on my own extensive discussions with therapists who have worked with these compounds, I personally believe psychedelic therapies have the potential to become first-line treatments - and, over time, even potentially play a role in prevention.

Thank you, @realDonaldTrump, for today’s important signal of support, and @joerogan for driving it!

Most importantly, thank you to everyone working behind the scenes to make this possible today - and to the fellow drug developers advancing these therapies.

This has been, and will continue to be, a truly collaborative effort. You can all be proud of the meaningful difference you are about to make for the millions of patients in need.

[Peter Keks @PeterKeks1]

@yourfriendSOMMI

[yourfriendSOMMI ❤️💛💚💙 @yourfriendSOMMI]

❤️💛💚💙

Grow some Balls

[i cant even productions @icantevenfilms]

Monitoring the Situation

[Andrew Tate @Cobratate]

RETWEET TO INCREASE THE SPELL

[International Cyber Digest @IntCyberDigest]

❗️Essex police shut down their live facial recognition cameras because they were catching too many black people

At the same time, they admitted the cameras rarely picked up anyone who wasn't already on the watchlist.

The system was accurate. They just didn't like the results.

[Haytham Kaafarani @hayfarani]

I am a US citizen & Surgeon who took care of the Boston Maraton Bombing victims in 2013. I paid for 7 years to own a small apartment in downtown #Beirut for my 3 kids to enjoy summers there. Today, #Israel reduced my dream home to rubble, with american weapons, paid by my taxes.

[Christian Angermayer @C_Angermayer]

$ATAI is currently covered by 13 analysts, with price targets spanning $7 to $25.

I believe though that the view of most investors and analysts on @ataibeckley appears largely anchored only to the initial lead indication and drug we are pursuing: treatment-resistant depression (TRD) for BPL-003 (5-MeO-DMT).

In my view, they underappreciate the broader product portfolio, including VLS-01 (DMT) for TRD and EMP-01 (R-MDMA) for social anxiety disorder, but more importantly, I believe they materially underestimate the long-term total addressable market (TAM) for psychedelic medicines.

IMO, one structural factor could ultimately expand that TAM significantly: Many serious diseases are far easier to prevent than to treat after onset. While this may sound obvious, the traditional healthcare system has largely been built around treating illness rather than preventing it.

That paradigm is beginning to change. The rapid adoption of GLP-1 drugs from $LLY and $NVO demonstrates how quickly the market can shift toward preventive and even lifestyle-enhancing medicine.

Read more about it in my latest blog post:

[Psychedelic Alpha @Psyched_Alpha]

AtaiBeckley Details Phase 3 Design for 5-MeO-DMT in TRD After ‘Successful’ FDA Meeting

Read more: https://t.co/lTLQzMCV3T

[Patriot🇺🇸Newswire @NewswirePatriot]

Mayor Mamdani REFUSES to honor this Officer, but we should. 🎖

NYPD Chief Aaron Edwards first joined the force after Muslims attacked his city on 9/11.

23 years later, he was able to save New Yorkers lives from another Muslim attack.

When 2 Islamic terrorist began throwing IEDs into a crowd of conservative protesters, Chief Edwards didn't hesitate to act.

Edwards jumped a barricade and threw himself on the terrorist holding a LIT explosive with complete disregard for his own life.

Edwards tackled the suspect and secured the IED before it could explode, saving everyone in the crowd.

Chief Edwards deserves to be recognized for his bravery and self-sacrifice, even when cowardly Mayors stay silent.

[Joey CoCo Diaz @madflavor]

Its Monday…….The World don’t owe you Dick!

[Roddy 🇨🇦 @RodKahx]

X is blocking this video. You know what to do.

[Peter Keks @PeterKeks1]

@KimDotcom

[Resist CBDC 🏁 @Resist_CBDC]

No one wants Digital ID.
No one asked for CBDC.
No one voted for the NWO.
No one needs a carbon wallet.
No one wants more mRNA injections.
No one is safer with 24/7 surveillance.
No one chose to surrender their liberty.
No one agreed to end national sovereignty.

[SMX 🇺🇸 @iam_smx]

So the EU didn’t just impose a massive fine on X, they even fined Elon Musk himself.

It’s obvious they’re targeting him directly because they can’t stand what he says or what he stands for.

At this point, action needs to be taken against the people coordinating this attack.

[Peter Keks @PeterKeks1]

@Hexologist31

[Hexo 🇺🇸 @Hexologist31]

In a wonderful world, the Airdrop would be to the people that are Holding T-Shares.